Can a weekly shot keep metabolism from slowing after weight loss?

NCT ID NCT07757087

Recruiting now Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This trial investigates whether an investigational drug called NNC0487-0111, given as a once-weekly injection, can change how much energy the body uses in adults with overweight or obesity. It compares the drug against a low-calorie diet and a placebo, focusing on metabolic rates like sleeping and resting energy expenditure after weight loss. The goal is to see if the drug might help counter the metabolic slowdown that often follows weight loss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NNC0487-0111, an investigational drug given as a weekly injection
What this could lead to: If successful, this could point toward a treatment that helps maintain weight loss by counteracting the body's natural slowdown in metabolism.
What could go wrong: This is an early-phase trial, so the drug may not affect metabolism as hoped, and side effects are not yet fully known. Results may not apply to all people with obesity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Aarhus Universitetshospital, Steno Diabetes Center Aarhus
RECRUITING

Aarhus N, 8200, Denmark
Maastricht University-NUTRIM-Dep Human Biology-Obesity
NOT_YET_RECRUITING

Maastricht, 6211 LK, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.